US 9771585
miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)
granted A61PA61P35/00A61P35/02
Quick answer
US patent 9771585 (miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)) held by MIRAGEN THERAPEUTICS, INC. expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- MIRAGEN THERAPEUTICS, INC.
- Grant date
- Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61P, A61P35/00, A61P35/02, A61P43/00